Volume 11, Number 10—October 2005
Research
Community-associated Methicillin-resistant Staphylococcus aureus, Minnesota, 2000–2003
Jessica M. Buck*
, Kathryn Como-Sabetti*, Kathleen H. Harriman*, Richard N. Danila*, David J. Boxrud*, Anita Glennen*, and Ruth Lynfield*
, Kathryn Como-Sabetti*, Kathleen H. Harriman*, Richard N. Danila*, David J. Boxrud*, Anita Glennen*, and Ruth Lynfield*
Table 2
Community-associated methicillin-resistant Staphylococcus aureus invasive disease and skin and soft tissue infection (SSTI) patient demographics*
| Characteristic | Invasive disease patient (n = 65) | SSTI patient (n = 586) | OR (95% CI) |
|---|---|---|---|
| Median age, y | 28 | 24 | NS |
| Sex (male), no. (%) | 43 (66) | 296 (51) | 1.89 (1.10–3.24) |
| Race, no. (%) | |||
| White† | 33 (51) | 254 (43) | NS |
| Unknown | 10 (15) | 105 (18) | |
| Nonwhite† | 21 (32) | 223 (38) | NS |
| Black | 14 (21) | 125 (21) | |
| Native American | 6 (9) | 82 (14) | |
| Asian | 1 (0.5) | 4 (0.7) | |
| Other | 1 (0.5) | 12 (0.2) | |
| Median income (US)‡ | $38,237 | $38,237 | NS |
| Patients hospitalized, no. (%)§ |
49 (75) |
173(31) |
6.89 (3.81–12.4) |
| (n = 58) |
(n = 515) |
||
| Presence of underlying condition, no. (%) | 31 (53) | 183 (36) | 2.08 (1.21–3.60) |
| Immunosuppressive therapy,¶ no. (%) | 3 (5) | 3 (0.6) | 9.31 (1.83–47.2) |
| Solid organ malignancy, no. (%) | 2 (4) | 2 (0.4) | 9.16 (1.27–66.3) |
| Diabetes, no. (%) | 9 (16) | 41 (8) | NS |
| Current smoker, no. (%) | 12 (21) | 55 (11) | 2.18 (1.09–4.37) |
| Emphysema/COPD, no. (%) | 3 (5) | 2 (0.4) | 13.9 (2.29–85.5) |
| Injection drug use, no. (%) | 3 (5%) | 5 (1) | 5.56 (1.29–23.9) |
*OR, odds ratio; CI, confidence interval; NS, not significant; COPD, chronic obstructive pulmonary disease.
†Race was calculated by using the number of cases with known race as the denominator.
‡Based on the mean household income in the zip code of each case-patient (source: 2000 US Census).
§Calculated by using the number of cases with known hospitalization status. Twenty-four SSTI patients had unknown hospitalization status.
¶Defined as long-term systemic steroid use, excluding topical creams, steroids used only for short-course treatment, and inhaled steroids used for asthma.
Page created: February 22, 2012
Page updated: February 22, 2012
Page reviewed: February 22, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.